Market research
NEULANDLAB.NSE Neuland Laboratories Limited
NSE INR Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 244B
- P/E ratio
- 49.11
- Analyst target
- 24678.5
- Dividend yield
- 0.0%
- Beta
- 0.28
Profile
Instrument facts
- Exchange
- NSE
- Currency
- INR
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- INE794A01010
- Market cap
- 244B
- P/E ratio
- 49.11
- Analyst target
- 24678.5
- Dividend yield
- 0.0%
- Beta
- 0.28
About
About Neuland Laboratories Limited
Neuland Laboratories Limited engages in the manufacture and sale of active pharmaceutical ingredients (APIs) in India, Europe, the United States, and internationally. It also provides custom manufacturing solutions, generic drug substances, as well as peptide APIs and synthesis services. The company serves generic companies, regional and domestic pharmaceutical manufacturers, distributors, and other pharmaceutical and biotechnology companies. Neuland Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
Research context
Neuland Laboratories Limited appears in PyInvesting’s India Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- INR
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the NEULANDLAB.NSE discussion.
5 years, 6 months ago
Neuland Laboratories Limited is currently in a long term uptrend where the price is trading 29.3% above its 200 day moving average.
From a valuation standpoint, the stock is 31.1% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.3.
Neuland Laboratories Limited's total revenue rose by 20.4% to $2B since the same quarter in the previous year.
Its net income has increased by 140.6% to $267M since the same quarter in the previous year.
Finally, its free cash flow grew by 64.4% to $801M since the same quarter in the previous year.
Based on the above factors, Neuland Laboratories Limited gets an overall score of 5/5.